Research and Markets (http://www.researchandmarkets.com/research/44ln6w/semaglutide_type)
has announced the addition of the "Semaglutide
(Type 2 Diabetes) - Forecast and Market Analysis to 2022"
report to their offering.
The type 2 diabetes market is mature and crowded with inexpensive
generics. Despite being marked by a late-stage pipeline filled with
me-too drugs, this market will undergo substantial growth between 2012
and 2022, more than doubling over this period.
The main drivers of growth will be the dramatic increase in disease
prevalence and physicians' efforts to delay disease progression and
reduce the costly burden of diabetic complications through the use of
combination therapies and novelbranded drugs.
Semaglutide is a long-acting GLP-1 analog being developed by Novo
Nordisk, currently in Phase III clinical trials. Two Bristol-Myers
Squibb medicines (short-acting Byetta and long-acting Bydureon), Novo
Nordisk's long-acting Victoza and Sanofi's short-acting Lyxumia are
marketed drugs in the same class of treatment for type 2 diabetes.
- Overview of type 2 diabetes, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
- Detailed information on Semaglutide including product description,
safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Semaglutide for the top ten countries from 2012 to
- Sales information covered for the US, France, Germany, Italy, Spain,
the UK, Japan, Brazil, India and China.
Key Topics Covered:
1.1 List of Tables
1.2 List of Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
For more information visit http://www.researchandmarkets.com/research/44ln6w/semaglutide_type
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To NFVZone's Homepage ]